Advertisement

Topics

Centrexion Therapeutics Company Profile

04:02 EST 21st January 2018 | BioPortfolio

Centrexion Therapeutics, Inc., is focused on developing and commercializing new, non-opioid and non-surgical treatments for moderate to severe chronic pain. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global problem of chronic pain.


News Articles [669 Associated News Articles listed on BioPortfolio]

Centrexion raises $67 million to take lead therapy into Phase III

USA-based Pain specialist Centrexion Therapeutics has raised $67 million in a Series D financing to fund…

Centrexion Therapeutics’ CNTX-4975 Receives Fast Track Designation from the FDA for Treatment of Knee Osteoarthritis Pain

BOSTON–(BUSINESS WIRE)–Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that t...

Centrexion secures funding to begin trial of knee osteoarthritis pain drug

Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).

Centrexion’s $67M Series D round to fund Phase 3 pain studies

Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.

Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III.

Centrexion raises $67mm in Series D round to fund Phase III trial for pain candidate CNTX4975

Pain-focused Centrexion Therapeutics Corp. raised $67mm in a Series D financing led by New Enterprise Associates. New and returning investors, including Quan Capital, ArrowMark Partners, investment fu...

Centrexion To Present Clinical Data From Pipeline Of Chronic Pain Treatments At The 11th Annual Pain And Migraine Therapeutics Summit

  Life Sciences Jobs   ...

Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017

Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in acti...

PubMed Articles [408 Associated PubMed Articles listed on BioPortfolio]

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Is the Eye an Extension of the Brain in Central Nervous System Disease?

Non-protein biologic therapeutics.

While the therapeutic biologics are dominated by therapeutic proteins, particularly monoclonal antibodies, a wide range of non-protein therapeutic biologics are rapidly gaining ground both in clinical...

Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099.

Eyes on New Product Development.

Clinical Trials [125 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1184 Associated Companies listed on BioPortfolio]

Centrexion Therapeutics, Corp.

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-...

Centrexion Therapeutics

Centrexion Therapeutics, Inc., is focused on developing and commercializing new, non-opioid and non-surgical treatments for moderate to severe chronic pain. Centrexion Therapeutic...

Centrexion Therapeutics Corporation

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-o...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Centrexion Therapeutics" on BioPortfolio

We have published hundreds of Centrexion Therapeutics news stories on BioPortfolio along with dozens of Centrexion Therapeutics Clinical Trials and PubMed Articles about Centrexion Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Centrexion Therapeutics Companies in our database. You can also find out about relevant Centrexion Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement

 

Relevant Topics

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...


Corporate Database Quicklinks



Searches Linking to this Company Record